About Hilleman

Hilleman Laboratories is a global vaccine research & development organization focused on making affordable vaccines using innovation to address gaps that exist in low resource settings. Hilleman Labs acts as a catalyst in bridging the gap between academic research and product development by targeting novel vaccines and increasing the efficiency of existing vaccines.

Know More

Vision

Developing vaccines for global health

Company Presentation

mission

Hilleman Laboratories is committed to developing high impact, affordable vaccines for people in developing countries in an innovative and sustainable manner.

In The News

  • Hilleman Labs successfully completes Phase I/II Clinical Trial of its Heat Stable Rotavirus Vaccine (HSRV)

    October 12th, 2017

    Making headway towards providing the developing nations an affordable and easy-to-use Heat Stable Ro

    Know More
  • Hilleman Labs achieves successful outcome of Phase I/II Clinical Trial of its Oral Cholera Vaccine Hillchol

    October 12th, 2017

    Delivering on its mission to develop affordable vaccines for global health, Hilleman Laboratories to

    Know More
  • Hilleman Laboratories receives Indo-Swedish grant for developing - Oral Cholera Vaccine (OCV)

    September 28th, 2017

    28th September, 2017, New Delhi: Hilleman Laboratories, a joint-venture partnership between MSD and

    Know More
  • Building Healthy Partnership

    May 04th, 2017

    Though India has scored several successes such as eradication of polio and reduction in the rates of

    Know More
  • Hilleman Laboratories signs MoU with NICED, ICMR to develop Shigella Vaccine

    March 29th, 2017

    March 29th, 2017, New Delhi: Hilleman Laboratories, a joint-venture partnership between MSD and Well

    Know More

Science & Innovation

Our Approach

We have established modern research and development laboratories to play a crucial role in the process of health development in India and other under-developed countries.

Vaccine Innovation

We are collaborating with the global public health community on the development of optimized vaccines with target product profiles relevant to low income countries.

Current R&D

The World Health Organization estimates that 600,000 children under the age of 5 die annually due to rotavirus diarrhoea and another two million are hospitalized.